Satellite Symposium at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Task Force meeting
The Road Ahead: CD30-targeted therapy in lymphoma
25 October 2014 08:00–09:00
Pullman Paris Bercy‎, Paris, France

After having participated in the satellite symposium, the pathologist will:

  1. Be aware of the emerging treatment options for cutaneous lymphoma patients, focusing on CD30 as therapeutic target
  2. Understand the MoA of CD30 targeting agents and be knowledgeable about brentuximab vedotin as a clinically relevant treatment option for patients with relapsed or refractory sALCL
  3. Feel comfortable with how to select eligible patients to enrol in the ongoing PTCL or CTCL clinical trials receiving brentuximab vedotin
  4. Understand which other difficult to treat haematological malignancies express CD30
  5. Be aware of clinical trials with CD30 targeting therapy in relapsed/refractory PTCL and CTCL


08:00-08:05 Welcome and introduction (Prof. Whittaker)
08:05-08:20 Rationale for targeting CD30 in cutaneous lymphoma (Prof. Willemze)
08:20-08:35 Clinical evidence and ongoing trials of CD30-targeting agents (Prof. Illidge)
08:35-08:50 The changing landscape of CTCL management (Prof. Whittaker)
08:50-09:00 Q & A, closing (Prof. Whittaker)








Sean Whittaker
United Kingdom

Timothy Illidge
United Kingdom

Rein Willemze
This meeting is an
Excerpta Medica activity.
Support for this educational activity is provided by
Takeda Oncology.